Studies have indicated that the mutation in CTCF is associated with the onset of breast cancer, prostate cancer, and Wilms' tumors (Oh et al., 2017), suggesting that this subtype mainly contains the tumors in early stages. Here, CTCF is linked to prostate carcinoma.